TABLE 3.
Odds ratios (OR) and 95% confidence intervals for all‐cause mortality among patients with cancer and COVID‐19
| Characteristic | N (events) | OR (95% CI) |
|---|---|---|
| Sex | ||
| Female | 728 (77) | 1 |
| Male | 539 (96) | 1.5 (1.1, 2.2) |
| Age categories | ||
| <60 | 442 (16) | 1 |
| 60‐69 | 325 (36) | 2.7 (1.5, 5.1) |
| ≥70 | 500 (121) | 7.6 (4.3, 13.5) |
| Race/ethnicity | ||
| Non‐Hispanic white | 559 (93) | 1 |
| Non‐Hispanic black | 425 (53) | 0.7 (0.4, 1.0) |
| Hispanic/Latino | 54 (10) | 1.3 (0.6, 2.9) |
| Asian/Hawaiian/PI/other/unknown | 229 (17) | 0.4 (0.2, 0.7) |
| Annual household income | ||
| >30 k | 1078 (138) | 1 |
| 0‐30 k | 189 (35) | 2.0 (1.2, 3.3) |
| Comorbidities | ||
| Charlson comorbidity score | ||
| 0 | 426 (38) | 1 |
| 1 | 379 (39) | 0.8 (0.5, 1.4) |
| 2+ | 462 (96) | 1.6 (1.0, 2.6) |
| Surgery in the year prior to 2/1/2020, N (%) | 461 (64) | 0.8 (0.5, 1.1) |
| Hypertension | 411 (64) | 0.8 (0.5, 1.1) |
| Coagulopathy | 48 (11) | 1.4 (0.7, 3.0) |
| Pulmonary circulation disorders | 48 (15) | 2.6 (1.3, 5.3) |
| Obesity | 98 (6) | 0.4 (0.2, 1.0) |
| Malignancy type | ||
| Solid tumor site or neoplasm NOS | 1077 (141) | 1 |
| Hematological malignancy | 190 (32) | 1.1 (0.7, 1.8) |
| Cancer status | ||
| History of cancer | 548 (64) | 1 |
| Active | 719 (109) | 1.1 (0.7, 1.6) |
| Cancer treatment in the 30 days prior to 2/1/2020 (active cancers) | ||
| No treatment | 1175 (152) | 1 |
| Immune checkpoint inhibitors | 12 (6) | 5.2 (1.2, 22.3) |
| Chemotherapy | 39 (12) | 3.3 (1.3, 8.1) |
| Targeted therapies | 63 (12) | 0.8 (0.3, 1.7) |